A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors.

The combination of gene therapy and chemotherapy may increase the therapeutic efficacy in the treatment of patients. In this work, the cationic polymer prodrug/plasmid nanocomplexes were designed to in vivo synergistically treat drug-resistant breast tumors. Cationic β-cyclodextrin-polyethylenimine-Dox (PC-Dox) conjugates were prepared for carrying wt p53 plasmid in the form of PC-Dox/p53 nanocomplexes to achieve synergistic cancer therapeutic effects of drug and gene therapies. Such PC-Dox/p53 nanocomplexes ensure that both drug and gene can be delivered to the same cancer cells. The physicochemical properties and Dox release profiles of the PC-Dox conjugates, as well as their antitumor activities in vitro and in vivo, were determined. mRNA expression and western blot experiments also proved that co-delivery of Dox with wt p53 plasmid from PC-Dox/wt p53 complexes could promote wt p53 gene expression largely. By investigating anticancer efficacy via multi-drug resistant MCF-7/Adr breast cancer cells, it was found that PC-Dox/wt p53 complexes promoted the inhibition of tumor growth in vivo and prolonged the survival time of tumor-bearing mice. With the efficient ability to co-deliver drug and gene, such multifunctional PC-Dox/pDNA complexes should have great potential applications in cancer therapy.

[1]  A. Cuschieri,et al.  Progress in nanotechnology for healthcare , 2010, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[2]  Y. Tong,et al.  Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. , 2007, Biomaterials.

[3]  Guping Tang,et al.  Low Generation Polypropylenimine Dendrimer Graft β-cyclodextrin: An Efficient Vector for Gene Delivery System , 2008, Technology in cancer research & treatment.

[4]  A. Thor,et al.  Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. , 2001, Cancer research.

[5]  O. Halevy,et al.  p53 Mutations: Gains or losses? , 1991, Journal of cellular biochemistry.

[6]  Steve P. Rannard,et al.  Dendrimers: a new class of nanoscopic containers and delivery devices , 2003 .

[7]  P. Couvreur,et al.  Nanomedicines: A New Approach for the Treatment of Serious Diseases , 2007 .

[8]  A. Martini,et al.  Drug delivery systems for cancer drugs , 2003 .

[9]  T. A. Lister,et al.  Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species. , 2007, Cancer research.

[10]  A. Nudelman,et al.  Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines , 2006, Journal of Cancer Research and Clinical Oncology.

[11]  Marie C. M. Lin,et al.  The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. , 2009, Biomaterials.

[12]  Jun Li,et al.  Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. , 2010, Biomaterials.

[13]  Maria J. Vicent,et al.  Polymer-drug conjugates as modulators of cellular apoptosis , 2007, The AAPS Journal.

[14]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[15]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[16]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[17]  D. Noonan,et al.  Progress towards gene therapy for cancer. , 2000, Journal of experimental & clinical cancer research : CR.

[18]  Jianjun Cheng,et al.  Anticancer Polymeric Nanomedicines , 2007 .

[19]  P. Seth,et al.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. , 1997, Cancer research.

[20]  L. H. Reddy.  Drug delivery to tumours: recent strategies , 2005, The Journal of pharmacy and pharmacology.

[21]  Yen Wah Tong,et al.  Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. , 2009, Biomaterials.

[22]  R. Satchi‐Fainaro,et al.  Polymer therapeutics for cancer : Current status and future challenges , 2006 .

[23]  E. Alli,et al.  Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.

[24]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[25]  M. S. Orr,et al.  Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. , 1996, Biochemical pharmacology.

[26]  D. Gewirtz,et al.  Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. , 1994, Molecular pharmacology.

[27]  S. Shankar,et al.  Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. , 2003, Cancer research.

[28]  F. Alexis,et al.  Low molecular weight polyethylenimines linked by β‐cyclodextrin for gene transfer into the nervous system , 2006, The journal of gene medicine.

[29]  Charles M Perou,et al.  Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.

[30]  Guping Tang,et al.  Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-β-cyclodextrin or (2-hydroxypropyl)-γ-cyclodextrin , 2006 .

[31]  A. Levine,et al.  Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. , 1990, Biochimica et biophysica acta.

[32]  Huanchen Sha,et al.  Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. , 2007, Critical reviews in therapeutic drug carrier systems.

[33]  A. Moreno,et al.  Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. , 2002, Toxicology and applied pharmacology.

[34]  Guping Tang,et al.  A Novel Co-polymer Based on Hydroxypropyl α-Cyclodextrin Conjugated to Low Molecular Weight Polyethylenimine as an in Vitro Gene Delivery Vector , 2008, International journal of molecular sciences.